All Hot News Popular Media
«Merck» All Releases

Tue, 22 May 2018 18:21:00 +0000
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment for Squamous Non-Small Cell Lung Cancer (NSCLC) in Pivotal Phase 3 KEYNOTE-407 Trial
Dateline City:
KENILWORTH, N.J.

KEYTRUDA Has Now Demonstrated an Improved Survival Benefit in Advanced NSCLC in Five Phase 3 Trials

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-407 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with carboplatin-paclitaxel or nab-paclitaxel, as first-line treatment for metastatic squamous non-small cell lung cancer (sNSCLC), met the dual primary endpoints of overall survival (OS) and progression-free survival (PFS).

Language:
English
Contact:

For Merck & Co., Inc.
Media:
Pamela Eisele, 267-305-3558
or
Kristen Drake, 908-334-4688
or
Investors:
Teri Loxam, 908-740-1986
or
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Wed, 16 May 2018 21:05:00 +0000
Merck Announces Third-Quarter 2018 Dividend
Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.48 per share of the company’s common stock for the third quarter of 2018. Payment will be made on July 9, 2018 to shareholders of record at the close of business on June 15, 2018.

About Merck

Language:
English
Contact:

Merck
Media:
Tracy Ogden, 908-740-1747
Claire Gillespie, 267-305-0932
or
Investors:
Teri Loxam, 908-740-1986
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Tue, 08 May 2018 10:45:00 +0000
New Data from Merck’s Leading Immuno-Oncology Clinical Development Program in Over 25 Tumor Types to Be Presented at 2018 ASCO Annual Meeting
Dateline City:
KENILWORTH, N.J.

New and Long-term Overall Survival Data for KEYTRUDA ® (pembrolizumab) in Lung Cancer and Melanoma, Plus New Data in Renal Cell, Cervical, Merkel Cell, and Other Cancers

First-Time Lynparza ® (olaparib) Data in Combination with Abiraterone in Metastatic Prostate Cancer Under Merck and AstraZeneca Strategic Collaboration

New Data in Four Tumor Types Evaluating LENVIMA ® (lenvatinib) in Combination with KEYTRUDA Under Merck and Eisai Strategic Collaboration

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new combination and monotherapy data from Merck’s oncology portfolio, anchored by anti-PD-1 therapy KEYTRUDA, will be presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 1-5. More than 140 abstracts in over 25 tumor types have been accepted, including new and long-term data for KEYTRUDA across multiple types of cancer.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Claire Mulhearn, 908-740-6664
or
Investors:
Teri Loxam, 908-740-1986
or
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Thu, 03 May 2018 20:15:41 +0000
LYNPARZA® (olaparib) Tablets Receive EU Approval for the Treatment of Platinum-Sensitive Relapsed Ovarian Cancer
Dateline City:
KENILWORTH, N.J.

Women with Platinum-Sensitive Ovarian Cancer Now Have Access to Maintenance Therapy with AstraZeneca and Merck’s LYNPARZA, Regardless of BRCA status

LYNPARZA Has Over Five Years’ Efficacy and Safety Follow-Up Data

New Tablet Formulation Reduces Dosing to Two Tablets Twice Daily

KENILWORTH, N.J.--(BUSINESS WIRE)--

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Medicines Agency (EMA) has approved LYNPARZA® (olaparib) tablets (300 mg twice daily) for use as a maintenance therapy for patients with platinum-sensitive relapsed high-grade, epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete response or partial response to platinum-based chemotherapy, regardless of BRCA status.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
Courtney Ronaldo, 908-740-6132
or
Investors:
Teri Loxam, 908-740-1986
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Thu, 03 May 2018 10:45:00 +0000
Moderna and Merck Expand mRNA Cancer Vaccines Collaboration
Dateline City:
CAMBRIDGE, Mass. and KENILWORTH N.J.
Multimedia
All Other Multimedia:
image/jpeg iconModerna_Logo.jpg (204.7 KB)

Expansion Includes the Joint Development of Moderna’s KRAS Oncogene Program and Other Potential mRNA Cancer Vaccines; Merck to Make Equity Investment in Moderna

CAMBRIDGE, Mass. and KENILWORTH N.J. May 3, 2018Moderna Therapeutics and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced an expansion of their 2016 collaboration to develop and commercialize novel personalized messenger RNA (mRNA) cancer vaccines to now include shared antigen mRNA cancer vaccines including mRNA-5671, Moderna’s mRNA KRAS cancer vaccine.

Language:
English

read more


Tue, 01 May 2018 10:45:00 +0000
Merck Provides Update on KEYNOTE-407 Trial
Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-407 trial investigating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with carboplatin-paclitaxel or nab-paclitaxel as first line treatment for metastatic squamous non-small cell lung cancer (sNSCLC) met a pre-specified secondary endpoint of overall response rate (ORR) in an early cohort of participants at an interim analysis.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
Kristen Drake, 908-334-4688
or
Investors:
Teri Loxam, 908-740-1986
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Mon, 30 Apr 2018 10:45:00 +0000
Merck Announces First-Quarter 2018 Financial Results
Dateline City:
KENILWORTH, N.J.
  • First-Quarter 2018 Worldwide Sales Were $10.0 Billion, an Increase of 6 Percent, Including a 3 Percent Positive Impact from Foreign Exchange
  • First-Quarter 2018 GAAP EPS was $0.27, Reflecting a $1.4 Billion Aggregate Charge Related to the Formation of a Collaboration with Eisai; First-Quarter Non-GAAP EPS was $1.05
  • Company Narrows and Raises 2018 Full-Year Revenue Range to be Between $41.8 Billion and $43.0 Billion, Including an Approximately 2 Percent Positive Impact from Foreign Exchange
  • Company Lowers 2018 GAAP EPS Range to be Between $2.45 and $2.57; Narrows and Raises 2018 Full-Year Non-GAAP EPS Range to be Between $4.16 and $4.28, Including an Approximately 1 Percent Positive Impact from Foreign Exchange
  • Results from Phase 3 KEYNOTE-189 Study Presented at AACR 2018 and Published in The New England Journal of Medicine Showed KEYTRUDA in Combination with Pemetrexed and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous NSCLC
  • Data from KEYNOTE-189 is Now Under Review by Regulatory Authorities in the United States, Europe and Japan

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2018.

“Merck had a strong start to the year driven by KEYTRUDA, GARDASIL, BRIDION and Animal Health,” said Kenneth C. Frazier, Merck Chairman and CEO. “This provides good momentum as we continue to execute on our pillars of growth and look to deliver innovative medicines and vaccines that address unmet needs for patients around the world.”

Language:
English
Contact:

Merck
Media:
Tracy Ogden, (908) 740-1747
Claire Gillespie, (267) 305-0932
or
Investor:
Teri Loxam, (908) 740-1986
Michael DeCarbo, (908) 740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Mon, 23 Apr 2018 20:30:00 +0000
FDA Grants Priority Review to Merck’s sBLA for KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy Based on Results from Phase 3 KEYNOTE-189 Trial as First-Line Treatment of Metastatic Nonsquamous NSCLC
Dateline City:
KENILWORTH, N.J.

U.S. FDA Has Set a PDUFA Date of Sept. 23, 2018

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for KEYTRUDA®, the company’s anti-PD-1 therapy, based on results of the Phase 3 KEYNOTE-189 trial.

Language:
English
Contact:

Media:
Pamela Eisele, 267-305-3558
Kristen Drake, 908-334-4688
or
Investors:
Teri Loxam, 908-740-1986
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Sun, 22 Apr 2018 10:05:56 +0000
European Medicines Agency Validates Type II Variation for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy as First-Line Therapy in Metastatic Nonsquamous NSCLC, Based on Phase 3 KEYNOTE-189 Trial
Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that following validation by the European Medicines Agency (EMA), the centralized review process has begun for the company’s Type II Variation, which seeks approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with pemetrexed (ALIMTA®) and platinum chemotherapy (cisplatin or carboplatin) for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC).

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Kristen Drake, 908-740-6179
or
Investors:
Teri Loxam, 908-740-1986
or
Peter Dannenbaum, 908-740-1037

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Tue, 17 Apr 2018 13:00:00 +0000
Pivotal Phase 3 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Demonstrated Favorable Overall Response Against Certain Imipenem–Non-Susceptible Bacterial Infections
Dateline City:
KENILWORTH, N.J.

Company Plans to Submit New Drug Application in the United States

Results Presented at ECCMID 2018 Annual Meeting

KENILWORTH, N.J., April 22, 2018 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that a pivotal Phase 3 study of relebactam, the company’s investigational beta-lactamase inhibitor, in combination with imipenem/cilastatin, demonstrated a favorable overall response in the treatment of certain imipenem–non-susceptible bacterial infections, the primary endpoint, with lower treatment-emergent nephrotoxicity (kidney toxicity), a secondary endpoint, compared to a Colistin (colistimethate sodium) plus imipenem regimen.

Language:
English

read more


Tue, 17 Apr 2018 12:30:00 +0000
Merck Advances Clean Energy Goals with Invenergy
Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J., April 17, 2018 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Invenergy, North America’s largest privately held renewable energy company, today announced a Virtual Power Purchase Agreement (VPPA) that adds 60 megawatts (MW) of renewable energy to the electrical grid and supports Merck’s environmental sustainability goals. The electricity will be generated from Invenergy’s Santa Rita East wind farm, located approximately 70 miles west of San Angelo, Texas.

Language:
English
Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more


Mon, 16 Apr 2018 13:30:00 +0000
Merck Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease Vaccine
Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the company is beginning two Phase 3 studies of PCV-15 (V114), its investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease. The first study (ClinicalTrials.gov, NCT03480763) will evaluate the safety, tolerability and immunogenicity of PCV-15 followed by Pneumococcal Vaccine Polyvalent one year later in healthy adult subjects 50 years of age or older.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Skip Irvine, 267-305-0338
or
Investors:
Teri Loxam, 908-740-1986
or
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Sun, 15 Apr 2018 20:50:00 +0000
Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed (ALIMTA®) and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as First-Line Treatment for Advanced Nonsquamous NSCLC in Phase 3 KEYNOTE-189 Study
Dateline City:
KENILWORTH, N.J.

KEYTRUDA Combination Improved Overall Survival in Patients Regardless of PD-L1 Expression, Including Patients Who Tested Negative for PD-L1

Results Presented Today at AACR 2018 and Published in The New England Journal of Medicine Also Show Significant Improvement in Progression-Free Survival, with Risk of Progression or Death Reduced by Nearly Half

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from KEYNOTE-189, a pivotal Phase 3 trial evaluating KEYTRUDA®, Merck’s anti-PD-1 therapy, in combination with pemetrexed (ALIMTA®) and cisplatin or carboplatin for the first-line treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC).

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Kristen Drake, 908-334-4688
or
Investors:
Teri Loxam, 908-740-1986
or
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Sun, 15 Apr 2018 13:30:00 +0000
Updated Overall Survival Data for LYNPARZA® (olaparib) in gBRCA-mutated HER2-Negative Metastatic Breast Cancer Presented at AACR
Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today presented data from the Phase 3 OlympiAD trial showing the final overall survival (OS) results for LYNPARZA in metastatic breast cancer at the American Association for Cancer Research (AACR) Annual Meeting in Chicago from April 14-18.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Courtney Ronaldo, 908-740-6132
or
Investors:
Teri Loxam, 908-740-1986
or
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Mon, 09 Apr 2018 10:45:00 +0000
Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Disease Recurrence or Death by More than 40 Percent Compared to Placebo as Adjuvant Therapy in Resected, High-Risk Stage III Melanoma
Dateline City:
KENILWORTH, N.J., & BRUSSELS

KEYTRUDA is First Anti-PD-1 Therapy to Show Recurrence-Free Survival (RFS) Benefit Across Stage IIIA (> 1 mm Lymph Node Metastasis), IIIB and IIIC Melanoma

EORTC1325/KEYNOTE-054 Results Presented Today in Opening Plenary at AACR 2018 and Published in The New England Journal of Medicine

KENILWORTH, N.J., & BRUSSELS--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and the European Organisation for Research and Treatment of Cancer (EORTC), today announced findings from the Phase 3 EORTC1325/KEYNOTE-054 trial investigating KEYTRUDA®, Merck’s anti-PD-1 therapy, as adjuvant therapy in resected, high-risk stage III melanoma.

Language:
English
Contact:

Media:
Merck
Pamela Eisele, 267-305-3558
Elizabeth Sell, 267-305-3877
or
EORTC
Davi Kaur, +32 (0)2 774 1513
or
Investors:
Merck
Teri Loxam, 908-740-1986
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Fri, 06 Apr 2018 11:30:41 +0000
KEYTRUDA® (pembrolizumab) Monotherapy Met Primary Endpoint in Phase 3 KEYNOTE-042 Study, Significantly Improving OS as First-Line Therapy in Locally Advanced or Metastatic NSCLC Patients Expressing PD-L1 in at Least 1 Percent of Tumor Cells
Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-042 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC, including nonsquamous or squamous histologies) met its primary endpoint of overall survival (OS).

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
Kristen Drake, 908-740-6179
or
Investors:
Teri Loxam, 908-740-1986
Peter Dannenbaum, 908-740-1037

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more


Tue, 03 Apr 2018 10:00:00 +0000
Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination with KEYTRUDA® (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma
Dateline City:
WILMINGTON, Del. and KENILWORTH, N.J.

WILMINGTON, Del. and KENILWORTH, N.J. – April 6, 2018 –Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that an external Data Monitoring Committee (eDMC) review of the pivotal Phase 3 ECHO-301/KEYNOTE-252 study results evaluating Incyte’s epacadostat in combination with Merck’s KEYTRUDA® in patients with unresectable or metastatic melanoma determined that the study did not meet the primary endpoint of improving progression-free survival in the overall population compared to KEYTRUDA monotherapy.

Language:
English

read more


Mon, 02 Apr 2018 14:05:10 +0000
The European Medicines Agency Accepts Regulatory Submission for LYNPARZA® (olaparib) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer
Dateline City:
KENILWORTH, N.J.

If Approved, AstraZeneca and Merck’s LYNPARZA Would be the First PARP Inhibitor to Treat Patients with Breast Cancer in Europe

KENILWORTH, N.J.--(BUSINESS WIRE)--AstraZeneca and Merck (NYSE:MRK), known as MSD outside the US and Canada, today announced that the European Medicines Agency has validated for review the Marketing Authorization Application (MAA) for LYNPARZA® (olaparib) for use in patients with deleterious or suspected deleterious BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.

Language:
English
Contact:

Media:
Pamela Eisele, 267-305-3558
Courtney Ronaldo, 908-740-6132
Investor:
Teri Loxam, 908-740-1986
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Mon, 02 Apr 2018 10:45:00 +0000
Merck Receives 2018 ENERGY STAR Sustained Excellence Award
Dateline City:
KENILWORTH, N.J.

Company Receives EPA Honor for 13th Consecutive Year

KENILWORTH, N.J., April 2, 2018 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that it has received an ENERGY STAR 2018 Partner of the Year – Sustained Excellence Award from the U.S. Environmental Protection Agency (EPA) for its continued leadership in energy management in both the pharmaceutical and industrial sectors, and superior contributions to ENERGY STAR. Merck’s accomplishments will be recognized by the EPA and the U.S. Department of Energy at a ceremony in Washington, D.C. on April 20, 2018.

Language:
English

read more


Fri, 23 Mar 2018 10:00:00 +0000
Merck to Hold First-Quarter 2018 Sales and Earnings Conference Call on May 1
Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its first-quarter 2018 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, May 1. During the call, company executives will provide an overview of Merck’s performance for the quarter.

Language:
English
Contact:

Merck
Media:
Tracy Ogden, 908-740-1747
Claire Gillespie, 267-305-0932
or
Investors:
Teri Loxam, 908-740-1986
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more


Tue, 20 Mar 2018 20:05:00 +0000
Anticancer Agent LENVIMA® (lenvatinib mesylate) Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan, First Approval Worldwide for LENVIMA for HCC
Dateline City:
TOKYO & KENILWORTH, N.J.

First New Front-Line Treatment Option for HCC Approved in Japan in Nearly 10 Years

First Approval Under Global Strategic Collaboration Between Eisai Co., Ltd. and Merck

TOKYO & KENILWORTH, N.J.--(BUSINESS WIRE)--Eisai Co., Ltd. and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the multiple receptor tyrosine kinase inhibitor LENVIMA® (lenvatinib mesylate) has been approved in Japan for unresectable hepatocellular carcinoma (HCC). This is the first approval worldwide for LENVIMA for the indication of unresectable HCC and the first new systemic therapy to be approved in Japan for the front line treatment of HCC in approximately 10 years.

Language:
English
Contact:

Eisai Public Relations Department
+81-(0)3-3817-5120
or
Eisai Investor Relations
+81-(0)3-3817-3016
or
Merck Media Relations
Pamela Eisele, 267-305-3558
or
Ann Bush, 908-740-6677
or
Merck Investor Relations
Teri Loxam, 908-740-1986
or
Peter Dannenbaum, 908-740-1037

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more


Wed, 14 Mar 2018 22:30:00 +0000
Merck Announces Appointment of Jennifer Zachary as General Counsel
Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the appointment of Jennifer Zachary as general counsel, effective April 16, 2018. Zachary will be responsible for Merck’s global legal, security and aviation, and environmental, health and safety organizations, and be a member of Merck’s Executive Committee. She succeeds Michael J. Holston.

Language:
English
Contact:

Merck
Media:
Tracy Ogden, 908-740-1747
Claire Gillespie, 267-305-0932
or
Investors:
Teri Loxam, 908-740-1986
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@merck

read more


Tue, 13 Mar 2018 11:00:00 +0000
First-Line Lung Cancer Data and Other New Research from Merck’s Broad Oncology Program to be Presented at AACR Annual Meeting
Dateline City:
KENILWORTH, N.J.

Late-Breaker Presentation of Overall Survival and Progression-Free Survival Results from Pivotal Phase 3 KEYNOTE-189 Trial with KEYTRUDA ® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy in First-Line Treatment of Advanced Nonsquamous Non-Small Cell Lung Cancer

First-Time KEYTRUDA Data Including Recurrence-Free Survival from Phase 3 KEYNOTE-054 Study, in Collaboration with EORTC, in Patients with Stage III Surgically Resected High-Risk Melanoma

Additional Research with KEYTRUDA, Investigational STING Agonist (MK-1454) and Merck’s Collaboration with AstraZeneca for LYNPARZA ® (olaparib) to be Presented

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new research from Merck’s broad oncology clinical program – across several major tumor types, as monotherapy and in combination – will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Chicago from April 14-18.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Courtney Ronaldo, 908-740-6132
or
Investors:
Teri Loxam, 908-740-1986
or
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more


Wed, 07 Mar 2018 22:05:00 +0000
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) for Treatment of Advanced Cervical Cancer
Dateline City:
KENILWORTH, N.J.

First Filing Acceptance for an Anti-PD-1 Therapy in Cervical Cancer

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted a new supplemental Biologics License Application (sBLA) and granted Priority Review for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy. The application is seeking approval for KEYTRUDA as a treatment for patients with advanced cervical cancer with disease progression on or after chemotherapy.

Language:
English
Contact:

For Merck & Co., Inc.
Media:
Pamela Eisele, 267-305-3558
or
Ann Bush, 908-740-6677
or
Investors:
Teri Loxam, 908-740-1986
or
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more



Eisai Co., Ltd. and Merck Enter Global Strategic Oncology Collaboration for LENVIMA® (lenvatinib mesylate)
Dateline City:
TOKYO & KENILWORTH, N.J.

Companies to Jointly Develop and Commercialize LENVIMA, as Monotherapy and in Combination with Merck’s KEYTRUDA ® (pembrolizumab) for Multiple Cancer Types

Eisai Books LENVIMA Product Sales and Companies to Share Development and Marketing Costs Equally, as well as Gross Profits From LENVIMA

LENVIMA/KEYTRUDA Combination Already Granted U.S. FDA Breakthrough Therapy Designation for Renal Cell Carcinoma; Expanded Joint Development Program to Support 11 Additional Potential Indications Across Six Other Cancer Types

Merck’s Strong Commercial Footprint and Medical Expertise, Combined with Eisai’s Extensive Real-World Evidence for LENVIMA, Will Expedite Patient Access Worldwide for Current and Future Potential Indications

TOKYO & KENILWORTH, N.J.--(BUSINESS WIRE)--Eisai Co., Ltd. and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the companies have agreed upon a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA® (lenvatinib mesylate), an orally available tyrosine kinase inhibitor discovered by Eisai.

Language:
English
Contact:

Eisai Public Relations Department
+81-(0)3-3817-5120
or
Eisai Investor Relations
+81-(0)3-3817-3016
or
Merck Relations
Pamela Eisele, 267-305-3558
or
Ann Bush, 908-740-6677
or
Merck Investor Relations
Teri Loxam, 908-740-1986
or
Peter Dannenbaum, 908-740-1037

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more


view page: 7

Save Up to 50% on Brand Name Tires Plus Free Shipping at Bestusedtires.com!

Start: 03 Oct 2017 | End: 30 Apr 2018

The Smarter Way, Delivered - Try Dollar Shave Club!

Start: 03 Nov 2017 | End: 03 Nov 2018

Ticket and Travel Packages for the 2018 NCAA Men's Final Four in San Antonio.

Start: 06 Oct 2017 | End: 02 Apr 2018

Search All Amazon* UK* DE* FR* JP* CA* CN* IT* ES* IN* BR* MX
Booking.com B.V. is based in Amsterdam in the Netherlands. Ready for some statistics? Our 1,534,024 properties, including 860,482 holiday rentals, are located in 123,105 destinations in 229 countries and territories, and are supported internationally by 198 offices in 70 countries.
2013 Copyright © Techhap.com Mobile version 2015 | PeterLife & company
Skimlinks helps publishers monetize editorial content through automated affiliate links for products.
Terms of use Link at is mandatory if site materials are using fully or particulary.
Were treated to the site administrator, a cup of coffee *https://paypal.me/peterlife
Yandex.ru